Longeveron Inc. LGVN
We are a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Our lead investigational product candidate is laromestrocel, also referred to as Lomecel-B®.
Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. Laromestrocel possesses broad potential applications across a spectrum of disease areas. Our mission is to continue to advance the development and regulatory approval of laromestrocel in order to make it available for patients who may need it.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $1.2M | $2.4M | $709.0K | $1.2M | $708.0K | $55.0K | — |
| Cost of revenue | $396.0K | $508.0K | $488.0K | $725.0K | $716.0K | $3.8M | — |
| Gross profit | $803.0K | $1.9M | $221.0K | $497.0K | $590.0K | $1.8M | — |
| R&D | $12.0M | $8.1M | $9.1M | $9.4M | $7.1M | $2.7M | — |
| SG&A | $12.0M | $10.3M | $12.2M | $8.1M | $9.7M | $2.7M | — |
| Total operating expenses | $24.1M | $18.4M | $21.2M | $18.5M | $18.0M | $5.6M | — |
| Operating income | -$23.3M | -$16.5M | -$21.0M | -$18.0M | -$17.5M | -$3.8M | — |
| Interest expense | — | — | — | $1.4M | — | — | — |
| Pre-tax income | -$22.7M | -$16.0M | -$21.4M | -$18.8M | — | — | — |
| Income tax | $0 | $0 | $0 | $0 | — | — | — |
| Net income | -$22.7M | -$16.0M | -$21.4M | -$18.8M | -$17.0M | -$3.7M | — |
| EPS, basic | -1.29 | -2.62 | -10.22 | -0.90 | -0.90 | — | — |
| EPS, diluted | -1.29 | -2.62 | -10.22 | -0.90 | -0.90 | -0.23 | — |
| Shares, diluted (wtd. avg.) | 17.58B | 9.41B | 2.17B | 21.0M | 18.9M | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $4.7M | $19.2M | $4.9M | $10.5M | $25.7M | $816.0K | $1.9M |
| Short-term investments | — | $0 | $412.0K | $9.2M | $9.5M | — | — |
| Receivables | $104.0K | $84.0K | $111.0K | $218.0K | $55.0K | — | — |
| Total current assets | $5.5M | $19.6M | $5.8M | $20.3M | $35.4M | $1.8M | — |
| Property, plant and equipment | $1.8M | $2.4M | $2.5M | $2.9M | $3.1M | $3.6M | — |
| Other intangibles | $2.3M | $2.4M | $2.3M | $2.4M | $2.3M | $1.5M | — |
| Total assets | $10.3M | $25.6M | $12.1M | $27.4M | $42.8M | $9.2M | — |
| Accounts payable | $423.0K | $99.0K | $638.0K | $1.8M | $645.0K | $1.6M | — |
| Total current liabilities | $4.1M | $2.6M | $3.9M | $4.9M | $2.7M | $3.8M | — |
| Long-term debt | — | — | — | — | — | $311.0K | — |
| Total liabilities | $4.6M | $3.7M | $5.3M | $6.9M | $5.3M | $7.3M | — |
| Retained earnings | -$132.3M | -$109.6M | -$85.0M | -$62.8M | -$43.9M | — | — |
| Total equity | $5.7M | $21.9M | $6.7M | $20.5M | $37.5M | $2.0M | $4.4K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$18.6M | -$13.9M | -$19.0M | -$14.0M | -$9.6M | -$2.4M | — |
| Depreciation and amortisation | $800.0K | $700.0K | $700.0K | $700.0K | $1 | $1 | — |
| Stock-based compensation | $1.7M | $2.3M | $2.0M | $2.2M | $1.3M | $44.0K | — |
| Capital expenditure | $245.0K | $655.0K | $301.0K | $569.0K | $330.0K | $131.0K | — |
| Investing cash flow | -$595.0K | -$640.0K | $8.2M | -$677.0K | -$10.7M | -$261.0K | — |
| Financing cash flow | $4.7M | $28.8M | $5.3M | -$509.0K | $45.2M | $1.6M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-110664.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | $55.0K | $708.0K | $1.2M | $709.0K | $2.4M | $1.2M |
| Gross profit | — | $1.8M | $590.0K | $497.0K | $221.0K | $1.9M | $803.0K |
| Net income | — | -$3.7M | -$17.0M | -$18.8M | -$21.4M | -$16.0M | -$22.7M |
Recent filings and events
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Officer or director change Item 5.02
- Officer or director change Item 5.02
- Officer or director change Item 5.02
- Charter or fiscal year changed Item 5.03
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Officer or director change Item 5.02
- Results announced Item 2.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |